Literature DB >> 15239390

Imatinib mesylate in the treatment of chronic myelogenous leukemia.

Gautam Borthakur1, Jorge E Cortes.   

Abstract

Imatinib mesylate binds to the inactive conformation of BCR-ABL tyrosine kinase, suppressing the Philadelphia chromosome-positive clone in chronic myelogenous leukemia (CML). Clinical studies of imatinib have yielded impressive results in the treatment of all phases of CML. With the higher rates of complete cytogenetic response with imatinib, molecular monitoring of disease has become mandatory in assessing response and determining prognosis. The practical aspects of the treatment of CML with imatinib are discussed. The emergence of imatinib resistance, albeit in a small percentage of patients, has prompted an evaluation of innovative treatment strategies.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15239390     DOI： 10.1532/ijh97.04054

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  60 in total

1.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

Review 2.  Practical management of patients with chronic myeloid leukemia receiving imatinib.

Authors:  Michael W N Deininger; Stephen G O'Brien; John M Ford; Brian J Druker
Journal:  J Clin Oncol       Date:  2003-03-13       Impact factor: 44.544

3.  Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.

Authors:  A Hochhaus; A Reiter; S Saussele; A Reichert; M Emig; J Kaeda; B Schultheis; U Berger; P C Shepherd; N C Allan; R Hehlmann; J M Goldman; N C Cross
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

4.  Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT).

Authors:  T Fischer; C Reifenrath; G R Hess; M T Corsetti; S Kreil; J Beck; P Meinhardt; G Beltrami; B Schuch; H Gschaidmeier; R Hehlmann; A Hochhaus; A Carella; C Huber
Journal:  Leukemia       Date:  2002-07       Impact factor: 11.528

5.  Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.

Authors:  Thoralf Lange; Thomas Bumm; Sandra Otto; Haifa-Kathrin Al-Ali; Ines Kovacs; Daniela Krug; Thomas Köhler; Rainer Krahl; Dietger Niederwieser; Michael W N Deininger
Journal:  Haematologica       Date:  2004-01       Impact factor: 9.941

6.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

Authors:  Jean-Pierre J Issa; Guillermo Garcia-Manero; Francis J Giles; Rajan Mannari; Deborah Thomas; Stefan Faderl; Emel Bayar; John Lyons; Craig S Rosenfeld; Jorge Cortes; Hagop M Kantarjian
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

7.  Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

Authors:  Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Terry L Smith; Francis J Giles; Stefan Faderl; Deborah A Thomas; Guillermo Garcia-Manero; Jean-Pierre J Issa; Michael Andreeff; Steven M Kornblau; Charles Koller; Milosav Beran; Michael Keating; Mary Beth Rios; Jenny Shan; Debra Resta; Renaud Capdeville; Kimberly Hayes; Maher Albitar; Emil J Freireich; Jorge E Cortes
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

8.  Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.

Authors:  Lihui Wang; Kevin Pearson; Lynne Pillitteri; Julia E Ferguson; Richard E Clark
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

9.  The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.

Authors:  Thomas B Sneed; Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rios; B Nebiyou Bekele; Xian Zhou; Debra Resta; William Wierda; Stefan Faderl; Francis Giles; Jorge E Cortes
Journal:  Cancer       Date:  2004-01-01       Impact factor: 6.860

10.  BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

Authors:  Nicholas J Donato; Ji Yuan Wu; Jonathan Stapley; Gary Gallick; Hui Lin; Ralph Arlinghaus; Moshe Talpaz
Journal:  Blood       Date:  2003-01-15       Impact factor: 22.113
View more
  7 in total

1.  Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas.

Authors:  Boaz Karmazyn; Mervyn D Cohen; Samuel Gregory Jennings; Kent A Robertson
Journal:  Pediatr Radiol       Date:  2012-06-22

2.  Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan.

Authors:  Emi Matsuo; Yasushi Miyazaki; Chizuko Tsutsumi; Yoriko Inoue; Reishi Yamasaki; Tomoko Hata; Takuya Fukushima; Hideki Tsushima; Daisuke Imanishi; Yoshitaka Imaizumi; Masako Iwanaga; Mari Sakai; Koji Ando; Yasushi Sawayama; Daisuke Ogawa; Yasuhisa Kawaguchi; Kazuhiro Nagai; Kunihiro Tsukasaki; Shuichi Ikeda; Yukiyoshi Moriuchi; Shinichiro Yoshida; Miyuki Honda; Jun Taguchi; Yasuyuki Onimaru; Takeshi Tsuchiya; Masayuki Tawara; Sunao Atogami; Masaomi Yamamura; Hisashi Soda; Yoshiharu Yoshida; Yuji Matsuo; Hiroaki Nonaka; Tatsuro Joh; Yumi Takasaki; Chiyuki Kawasaki; Saburo Momita; Itsuro Jinnai; Kazutaka Kuriyama; Masao Tomonaga
Journal:  Int J Hematol       Date:  2007-02       Impact factor: 2.490

3.  The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts.

Authors:  Andreea M Bujor; Yoshihide Asano; Paul Haines; Robert Lafyatis; Maria Trojanowska
Journal:  Arthritis Rheum       Date:  2011-06

4.  Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia.

Authors:  Shin Nakayama; Tokiko Nagamura-Inoue; Kazuaki Yokoyama; Nobuhiro Ohno; Jun Ooi; Satoshi Takahashi; Kaoru Uchimaru; Toru Iseki; Arinobu Tojo
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

5.  Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group.

Authors:  Mari Sakai; Yasushi Miyazaki; Emi Matsuo; Yukiyoshi Moriuchi; Tomoko Hata; Takuya Fukushima; Yoshitaka Imaizumi; Daisuke Imanishi; Jun Taguchi; Masako Iwanaga; Hideki Tsushima; Yoriko Inoue; Yumi Takasaki; Takeshi Tsuchiya; Minori Komoda; Koji Ando; Kensuke Horio; Yuji Moriwaki; Shinya Tominaga; Hidehiro Itonaga; Kazuhiro Nagai; Kunihiro Tsukasaki; Chizuko Tsutsumi; Yasushi Sawayama; Reishi Yamasaki; Daisuke Ogawa; Yasuhisa Kawaguchi; Shuichi Ikeda; Shinichiro Yoshida; Yasuyuki Onimaru; Masayuki Tawara; Sunao Atogami; Satoshi Koida; Tatsuro Joh; Masaomi Yamamura; Yuji Matsuo; Hisashi Soda; Hiroaki Nonaka; Itsuro Jinnai; Kazutaka Kuriyama; Masao Tomonaga
Journal:  Int J Hematol       Date:  2009-03-06       Impact factor: 2.490

Review 6.  Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia--insights from mathematical model analyses.

Authors:  Ingo Roeder; Ingmar Glauche
Journal:  J Mol Med (Berl)       Date:  2007-07-28       Impact factor: 4.599

7.  New experimental and theoretical investigations of hematopoietic stem cells and chronic myeloid leukemia.

Authors:  Ingo Roeder; Mark d'Inverno
Journal:  Blood Cells Mol Dis       Date:  2009-05-02       Impact factor: 3.039
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.